Yosuke Izumi
Research Subjects
Research Interests
Yosuke Izumi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Akinori Miura
Department of Esopageal Surgery, Tokyo Metropolitan Komagone Hospital
7 shared publications Tsuyoshi Kato
Komagome Hospital
7 shared publicationsAkinori Miura
Komagome Hospital
3 shared publicationsKumiko Momma
Komagome Hospital
3 shared publicationsKumiko Monma
3 shared publications- Michitaka Honda
Department of Surgery, Tokyo Metropolitan Komagome Hospital
3 shared publications
Latest Publications
- 1 December 2012
- Vol. 109 (12) , 2066-73
[A case of pneumatosis cystoides intestinalis receiving chemotherapy for esophageal and tonsillar cancers].
A man in his 50, underwent chemotherapy for esophageal and tonsillar cancers. Diarrhea appeared on the 4th day and worsened daily. On the 12th day, free air was pointed out on abdominal X-ray and he consulted our department. At that time, there was no peritoneal irritation sign. Though CT showed pneumatosis and free air, there were neither perforation nor intestinal necrosis, therefore we diagnosed pneumatosis cystoides intestinalis (PCI). Conservative management was performed. He could ingest orally on the 14th day and was discharged on the 37th day. After that, chemotherapy was performed on several occasions for cancer, but there was no recurrence of PCI.
- 1 December 2012
- Vol. 109 (12) , 2066-73
[A case of pneumatosis cystoides intestinalis receiving chemotherapy for esophageal and tonsillar cancers].
A man in his 50, underwent chemotherapy for esophageal and tonsillar cancers. Diarrhea appeared on the 4th day and worsened daily. On the 12th day, free air was pointed out on abdominal X-ray and he consulted our department. At that time, there was no peritoneal irritation sign. Though CT showed pneumatosis and free air, there were neither perforation nor intestinal necrosis, therefore we diagnosed pneumatosis cystoides intestinalis (PCI). Conservative management was performed. He could ingest orally on the 14th day and was discharged on the 37th day. After that, chemotherapy was performed on several occasions for cancer, but there was no recurrence of PCI.
- 18 October 2011
- Published by Springer Nature in Esophagus
- Vol. 8 (4) , 267-272
Minimally invasive esophagectomy: evaluation of mediastinal lymphadenectomy for T1b thoracic esophageal cancer
- 18 October 2011
- Published by Springer Nature in Esophagus
- Vol. 8 (4) , 267-272
Minimally invasive esophagectomy: evaluation of mediastinal lymphadenectomy for T1b thoracic esophageal cancer
- 21 December 2010
- Published by Springer Nature in Esophagus
- Vol. 7 (4) , 225-229
Linitis plastica-type adenocarcinoma of the esophagus: a case report
- 21 December 2010
- Published by Springer Nature in Esophagus
- Vol. 7 (4) , 225-229
Linitis plastica-type adenocarcinoma of the esophagus: a case report
- 1 November 2010
- Vol. 37 (12) , 2385-7
[Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
The patient suffering from getting something lodged was admitted to our hospital in October 2008. He was diagnosed as hypopharyngeal cancer (cT2N1M0, cStage III) and cervical esophageal cancer (cT2N1M0, cStage III). Firstly he was administered 5-FU, DXR and CDDP as induction chemotherapy. The response evaluation was PR according to RECIST criteria. After the induction chemotherapy, he was treated with chemoradiotherapy (64.8 Gy/54 fr, concurrent with weekly DOC 10 mg/m2). Since cervical lymph node metastases were still remaining with complete response of the primary sites, we performed a neck lymph node dissection as salvage surgery in July 2009. There has been no evidence of recurrence after the salvage surgery.
- 1 November 2010
- Vol. 37 (12) , 2385-7
[Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
The patient suffering from getting something lodged was admitted to our hospital in October 2008. He was diagnosed as hypopharyngeal cancer (cT2N1M0, cStage III) and cervical esophageal cancer (cT2N1M0, cStage III). Firstly he was administered 5-FU, DXR and CDDP as induction chemotherapy. The response evaluation was PR according to RECIST criteria. After the induction chemotherapy, he was treated with chemoradiotherapy (64.8 Gy/54 fr, concurrent with weekly DOC 10 mg/m2). Since cervical lymph node metastases were still remaining with complete response of the primary sites, we performed a neck lymph node dissection as salvage surgery in July 2009. There has been no evidence of recurrence after the salvage surgery.
- 1 January 2010
- Vol. 37 (1) , 71-5
[Usefulness of induction chemotherapy followed by chemo-radiotherapy for patients with advanced cervical esophageal cancer].
To obtain a good prognosis and preserve laryngeal function is one of the most important issues for patients with advanced cervical esophageal cancer. It is reported that induction chemotherapy (ICT) followed by concurrent chemoradiotherapy (CRT) is useful. We treated 8 consecutive patients with advanced cervical esophageal cancer by ICT and following CRT between 2003 and 2006. The regimen of ICT was FAP therapy (fluorouracil 1,000 mg/day and cisplatin 20mg/day on days 1-5, and doxorubicin 50mg/day on day 1) every 4 weeks. After 2-4 courses of FAP therapy, low-dose FP-CRT (fluorouracil 200mg/24 hours/day and cisplatin 5mg/day with radiation of 60-66 Gy, 2 Gy/day) were given. Effect of ICT was PR in 5 cases, SD in 1 case, and PD in 2 cases. Furthermore, the effect of ICT+CRT was CR in 5 cases and PD in 3 cases. The one-year survival rate was 62. 5%. Grade 3 hematological toxicity related to ICT was observed in 1 patient (12.5%). Grade 3 anorexia and esophagitis related to CRT were observed in 3 patients (37.5%) and 2 patients (25.0%), respectively. Radiation pneumonitis as a late toxicity occurred in 1 patient (12.5%). The therapeutic effect of ICT and CRT was suggested to be useful for patients with advanced cervical esophageal cancer because it was performed safely with no serious adverse effect and the outcome of ICT predicted the effect of the subsequent CRT.
- 1 January 2010
- Vol. 37 (1) , 71-5
[Usefulness of induction chemotherapy followed by chemo-radiotherapy for patients with advanced cervical esophageal cancer].
To obtain a good prognosis and preserve laryngeal function is one of the most important issues for patients with advanced cervical esophageal cancer. It is reported that induction chemotherapy (ICT) followed by concurrent chemoradiotherapy (CRT) is useful. We treated 8 consecutive patients with advanced cervical esophageal cancer by ICT and following CRT between 2003 and 2006. The regimen of ICT was FAP therapy (fluorouracil 1,000 mg/day and cisplatin 20mg/day on days 1-5, and doxorubicin 50mg/day on day 1) every 4 weeks. After 2-4 courses of FAP therapy, low-dose FP-CRT (fluorouracil 200mg/24 hours/day and cisplatin 5mg/day with radiation of 60-66 Gy, 2 Gy/day) were given. Effect of ICT was PR in 5 cases, SD in 1 case, and PD in 2 cases. Furthermore, the effect of ICT+CRT was CR in 5 cases and PD in 3 cases. The one-year survival rate was 62. 5%. Grade 3 hematological toxicity related to ICT was observed in 1 patient (12.5%). Grade 3 anorexia and esophagitis related to CRT were observed in 3 patients (37.5%) and 2 patients (25.0%), respectively. Radiation pneumonitis as a late toxicity occurred in 1 patient (12.5%). The therapeutic effect of ICT and CRT was suggested to be useful for patients with advanced cervical esophageal cancer because it was performed safely with no serious adverse effect and the outcome of ICT predicted the effect of the subsequent CRT.
- 1 January 2009
- Published by Japan Broncho-Esophagological Society in Nihon Kikan Shokudoka Gakkai Kaiho
- Vol. 60 (3) , 262-267
Evaluation of Second-Line Chemotherapy with Docetaxel and Nedaplatin for Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus
- 1 January 2009
- Published by Japan Broncho-Esophagological Society in Nihon Kikan Shokudoka Gakkai Kaiho
- Vol. 60 (3) , 262-267
Evaluation of Second-Line Chemotherapy with Docetaxel and Nedaplatin for Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus
- 1 October 2008
- Vol. 35 (10) , 1737-9
[Successful management of the recurrent esophageal cancer following esophagectomy at a different time with combined local treatment of chemoradiotherapy and hepatic arterial infusion chemotherapy].
A 63-year-old man who underwent radical resection for esophageal cancer (cStage III)was diagnosed with metastasis of the paraaortic lymph node 5 months after the surgery. He was treated with concomitant chemoradiotherapy (CRT)with low-dose FP(5-FU, CDDP)and 60 Gy of irradiation. The effect of CRT was a complete response. Seven months later, there was a metastasis to the liver(S4). He received systemic chemotherapy(5-FU, ADR, CDDP: FAP), but it was not effective, so hepatic arterial infusion chemotherapy(FAP)was performed. Hepatic artery infusion therapy( 5-FU 1,000 mg/3.5 h x ADR 10 mg/1 h x CDDP 10 mg/1 h)was given for 1 day at an interval of 2 weeks for 18 months. Since ADR reached the maximum dose, hepatic artery infusion of 5-FU(1,000 mg/3.5 h)and CDDP(10 mg/ 1 h)was continued for 14 months at an interval of 4 weeks. The recurrent lesion disappeared completely 9 months after beginning hepatic artery infusion therapy. The patient is alive 69 months after surgery without any evidence of recurrence. Most cases with recurrent esophageal cancer have multiple metastases, and the treatment is mainly systemic therapy. However, in a patient with recurrent tumors at different times, it is possible to achieve a complete response and long-time survival by local treatment with fewer side effects as in this case. Combined local treatments could be the second treatment option after failed systemic chemotherapy for recurrent tumors in patients with esophageal cancer. Further investigations are necessary.
- 1 October 2008
- Vol. 35 (10) , 1737-9
[Successful management of the recurrent esophageal cancer following esophagectomy at a different time with combined local treatment of chemoradiotherapy and hepatic arterial infusion chemotherapy].
A 63-year-old man who underwent radical resection for esophageal cancer (cStage III)was diagnosed with metastasis of the paraaortic lymph node 5 months after the surgery. He was treated with concomitant chemoradiotherapy (CRT)with low-dose FP(5-FU, CDDP)and 60 Gy of irradiation. The effect of CRT was a complete response. Seven months later, there was a metastasis to the liver(S4). He received systemic chemotherapy(5-FU, ADR, CDDP: FAP), but it was not effective, so hepatic arterial infusion chemotherapy(FAP)was performed. Hepatic artery infusion therapy( 5-FU 1,000 mg/3.5 h x ADR 10 mg/1 h x CDDP 10 mg/1 h)was given for 1 day at an interval of 2 weeks for 18 months. Since ADR reached the maximum dose, hepatic artery infusion of 5-FU(1,000 mg/3.5 h)and CDDP(10 mg/ 1 h)was continued for 14 months at an interval of 4 weeks. The recurrent lesion disappeared completely 9 months after beginning hepatic artery infusion therapy. The patient is alive 69 months after surgery without any evidence of recurrence. Most cases with recurrent esophageal cancer have multiple metastases, and the treatment is mainly systemic therapy. However, in a patient with recurrent tumors at different times, it is possible to achieve a complete response and long-time survival by local treatment with fewer side effects as in this case. Combined local treatments could be the second treatment option after failed systemic chemotherapy for recurrent tumors in patients with esophageal cancer. Further investigations are necessary.
- 1 April 2008
- Vol. 35 (4) , 629-31
[A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy].
A 70-year-old man with dysphagia was diagnosed as advanced esophageal cancer by a primary doctor, and he was admitted to our hospital for treatment in February, 2004. The pretreatment diagnosis was basaloid squamous carcinoma, Mt area, T4 (aorta) , N2 (No. 107) , M1 (liver), Stage IVb performed systemic chemotherapy by FAP (5-fluorouracil ( 5-FU)+doxorubicin (DXR)+cisplatin (CDDP) ) from March, 2004. After 4 courses, the local tumor almost entirely disappeared, and the liver metastasis was obviously reduced. We continued chemotherapy afterwards. As of March 31, 2007, he had local lesion CR and metastatic lesion PR. It is very important to perform FAP repeatedly, for local and metastatic lesion of esophageal cancer while maintaining the patient's general condition and avoiding adverse events.
- 1 April 2008
- Vol. 35 (4) , 629-31
[A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy].
A 70-year-old man with dysphagia was diagnosed as advanced esophageal cancer by a primary doctor, and he was admitted to our hospital for treatment in February, 2004. The pretreatment diagnosis was basaloid squamous carcinoma, Mt area, T4 (aorta) , N2 (No. 107) , M1 (liver), Stage IVb performed systemic chemotherapy by FAP (5-fluorouracil ( 5-FU)+doxorubicin (DXR)+cisplatin (CDDP) ) from March, 2004. After 4 courses, the local tumor almost entirely disappeared, and the liver metastasis was obviously reduced. We continued chemotherapy afterwards. As of March 31, 2007, he had local lesion CR and metastatic lesion PR. It is very important to perform FAP repeatedly, for local and metastatic lesion of esophageal cancer while maintaining the patient's general condition and avoiding adverse events.
- 1 January 2008
- Published by Japan Broncho-Esophagological Society in Nihon Kikan Shokudoka Gakkai Kaiho
- Vol. 59 (6) , 539-544
Evaluation of Combination Chemotherapy with 5-FU, Doxorubicin and CDDP in Patients with Advanced Esophageal Cancer
- 1 January 2008
- Published by Japan Broncho-Esophagological Society in Nihon Kikan Shokudoka Gakkai Kaiho
- Vol. 59 (6) , 539-544
Evaluation of Combination Chemotherapy with 5-FU, Doxorubicin and CDDP in Patients with Advanced Esophageal Cancer